On January 16, 2026, the U.S. Supreme Court agreed to hear Hikma Pharmaceuticals USA, Inc. v. Amarin Pharma, Inc., a patent ...

The Supreme Court on Jan. 16, 2026, agreed to decide a case about how generic companies can communicate to the market about their products, ...

The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drugmaker Hikma that puts so-called ...

The US Supreme Court will hear generic drug maker Hikma Pharmaceuticals USA Inc.'s challenge of an appeals court holding that ...

On Friday, the U.S. Supreme Court granted certiorari to a petition filed by patent owner Hikma Pharmaceuticals, taking up ...

A US Supreme Court fight over how branded drugs’ makers must plead induced infringement in “skinny-label” patent suits could ...

Mark Hartley digs deeper to uncover the real story behind Hikma Pharmaceuticals' big price drop, and whether it presents a ...

UK headquartered Hikma Pharmaceuticals, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc, have announced ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Hikma Pharmaceuticals PLC closed 34.62% below its 52-week high of £23.60, which the company achieved on February 13th.

Hikma Pharmaceuticals USA will invest $1 billion by 2030 to further expand its U.S. manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines ...

Hikma Pharmaceuticals PLC closed 34.53% below its 52-week high of £23.60, which the company achieved on February 13th.